SOLUBLE MACROPHAGE MARKER SCD163 PREDICTS OUTCOME IN BOTH CHEMOIMMUNOTHERAPY AND TARGETED THERAPY TREATED MANTLE CELL LYMPHOMA

Introduction: The outcome for patients with mantle cell lymphoma (MCL) has drastically improved new treatments directed towards the tumor immune microenvironment, where macrophages play an important role. In MCL, presence of M2 defined by CD163 expression in diagnostic biopsies been associated a worse prognosis. An alternative way to assess abundance is measuring level soluble serum (sCD163). Method: We aimed investigate prognostic value sCD163 131 MCL patients. was analyzed ELISA and cut-off á priori set median level. Results: found that high at diagnosis shorter progression-free survival (PFS) overall (OS) (log rank test p = 0.002 < 0.001, respectively) 81 newly diagnosed were subsequently treated chemoimmunotherapy. same seen cohort 50 relapsed, heavily pretreated, mainly within phase II Philemon-trial rituximab, ibrutinib lenalidomide test, PFS 0.016 OS 0.035). Low levels identified very good prognosis, as shown five-year 97%. There moderate correlation between tissue from lymph nodes (r 0.64, 0.014). higher TP53-mutated/p53 cases. However, association poor prognosis independent MIPI, Ki67, p53 status blastoid morphology, assessed multivariable cox proportional hazards model. Here, both (HR 3.48 95% CI: 1.42–8.54) 4.33 1.32–14.2). research funded by: study supported grants Swedish Cancer Society (19 0123 Pj 01 H 19 0109 SCIA, I.G), Medicine (I.G), Lions Research Fund Financial support SE granted European Union’s Horizon 2020 Framework Programme Innovation under agreement 754299, Cancerfonden (21 1561 Pj), Mats Paulsson’s Foundation research, innovation och societal development, Stefan Foundation, CREATE Health. Keywords: aggressive B-cell non-Hodgkin lymphoma, biomarkers, microenvironment Conflicts interests pertinent abstract M. Jerkeman Honoraria: AstraZeneca, Genmab, Kite/Gilead, Incyte, Orion, Novartis, Roche, Janssen, BMS, Abbvie (not related this study) funding: D. Molin Merck, Bristol-Myers Squibb, Takeda G. Enblad Consultant or advisory role Advisory Board Gilead Pierre Fabre, scientific advisor Elicera Therapeutics AB, Sprint Bioscience AB XNK Gilead, Fabre Roche C. E. Weibull Employment leadership position: War On Red Door Analytics Janseen Cilag S. Ek I. Glimelius Janssen-Cilag study).